User profiles for Andrew Menzies-Gow
 | Andrew Menzies-GowConsultant Physician, Royal Brompton Hospital Verified email at rbht.nhs.uk Cited by 12903 |
[HTML][HTML] Tezepelumab in adults and adolescents with severe, uncontrolled asthma
A Menzies-Gow, J Corren, A Bourdin… - … England Journal of …, 2021 - Mass Medical Soc
Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The …
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The …
Eosinophil's role remains uncertain as anti–interleukin-5 only partially depletes numbers in asthmatic airway
PT Flood-Page, AN Menzies-Gow, AB Kay… - American journal of …, 2003 - atsjournals.org
The role of eosinophils as effector cells in asthma pathogenesis has been questioned since
an anti–interleukin (IL)-5 monoclonal antibody (mepolizumab), which depleted blood and …
an anti–interleukin (IL)-5 monoclonal antibody (mepolizumab), which depleted blood and …
[HTML][HTML] Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics
P Flood-Page, A Menzies-Gow… - The Journal of …, 2003 - Am Soc Clin Investig
Eosinophil-derived TGF-β has been implicated in remodeling events in asthma. We hypothesized
that reduction of bronchial mucosal eosinophils with anti–IL-5 would reduce markers …
that reduction of bronchial mucosal eosinophils with anti–IL-5 would reduce markers …
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a …
…, C Emson, SE Wenzel, A Menzies-Gow… - The Lancet …, 2021 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies, …
stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies, …
[HTML][HTML] The biology of eosinophils and their role in asthma
CN McBrien, A Menzies-Gow - Frontiers in medicine, 2017 - frontiersin.org
This review will describe the structure and function of the eosinophil. The roles of several
relevant cell surface molecules and receptors will be discussed. We will also explore the …
relevant cell surface molecules and receptors will be discussed. We will also explore the …
Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British …
J Sweeney, CC Patterson, A Menzies-Gow, RM Niven… - Thorax, 2016 - thorax.bmj.com
Objective To determine the prevalence of systemic corticosteroid-induced morbidity in severe
asthma. Design Cross-sectional observational study. Setting The primary care Optimum …
asthma. Design Cross-sectional observational study. Setting The primary care Optimum …
Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic …
A Menzies-Gow, P Flood-Page, R Sehmi… - Journal of Allergy and …, 2003 - Elsevier
Background: Eosinophils develop from CD34 + progenitors under the influence of IL-5. Atopic
asthmatic individuals have increased numbers of mature eosinophils and eosinophil pro-…
asthmatic individuals have increased numbers of mature eosinophils and eosinophil pro-…
Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early-and late-phase …
A Menzies-Gow, S Ying, I Sabroe… - The Journal of …, 2002 - journals.aai.org
Eotaxin and eotaxin-2, acting through CCR3, are potent eosinophil chemoattractants both in
vitro and in animal models. In this study we examined the capacity of eotaxin and eotaxin-2 …
vitro and in animal models. In this study we examined the capacity of eotaxin and eotaxin-2 …
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies
JM FitzGerald, ER Bleecker, A Menzies-Gow… - The Lancet …, 2018 - thelancet.com
Background Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor α monoclonal
antibody that has been shown to significantly reduce asthma exacerbations and improve …
antibody that has been shown to significantly reduce asthma exacerbations and improve …
U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics
…, A Mazein, S Meah, A Maiser, A Menzies-Gow… - Journal of Allergy and …, 2017 - Elsevier
Background Asthma is a heterogeneous disease in which there is a differential response to
asthma treatments. This heterogeneity needs to be evaluated so that a personalized …
asthma treatments. This heterogeneity needs to be evaluated so that a personalized …